Merck KGaA (MKGAY.PK) and Pfizer Inc. (PFE) said that the Phase III Javelin Gastric 300 trial did not meet its primary endpoint of superior overall survival or OS with single-agent avelumab compared with physician's choice of chemotherapy.
from RTT - Biotech http://ift.tt/2iakfy7
via IFTTT
No comments:
Post a Comment